IFNA1 and severe acute respiratory syndrome: The delay in IFN-α response in SARS-CoV infection is associated with lung lesions and fatal outcome; preliminary in vitro experiments display that SARS-CoV-2 has more sensitivity than SARS-CoV to the IFN-α response and because of IFN-dependent induction response to SARS-CoV-2, type-I IFN is a therapeutic benefit in COVID-19 treatment [124–126].